Guidelines on the management of abnormal liver blood tests

Philip N. G. Newsome (Lead / Corresponding author), Rob Cramb, Suzanne M. Davison, John F. Dillon, Mark Foulerton, Edmund M. Godfrey, Richard Hall, Ulrike Harrower, Mark Hudson, Andrew Langford, Anne Mackie, Robert Mitchell-Thain, Karen Sennett, Nicholas C. Sheron, Julia Verne, Martine Walmsley, Andrew Yeoman

Research output: Contribution to journalArticle

65 Citations (Scopus)
180 Downloads (Pure)

Abstract

These updated guidelines on the management of abnormal liver blood tests have been commissioned by the Clinical Services and Standards Committee (CSSC) of the British Society of Gastroenterology (BSG) under the auspices of the liver section of the BSG. The original guidelines, which this document supersedes, were written in 2000 and have undergone extensive revision by members of the Guidelines Development Group (GDG). The GDG comprises representatives from patient/carer groups (British Liver Trust, Liver4life, PBC Foundation and PSC Support), elected members of the BSG liver section (including representatives from Scotland and Wales), British Association for the Study of the Liver (BASL), Specialist Advisory Committee in Clinical Biochemistry/Royal College of Pathology and Association for Clinical Biochemistry, British Society of Paediatric Gastroenterology, Hepatology and Nutrition (BSPGHAN), Public Health England (implementation and screening), Royal College of General Practice, British Society of Gastrointestinal and Abdominal Radiologists (BSGAR) and Society of Acute Medicine. The quality of evidence and grading of recommendations was appraised using the AGREE II tool. These guidelines deal specifically with the management of abnormal liver blood tests in children and adults in both primary and secondary care under the following subheadings: (1) What constitutes an abnormal liver blood test? (2) What constitutes a standard liver blood test panel? (3) When should liver blood tests be checked? (4) Does the extent and duration of abnormal liver blood tests determine subsequent investigation? (5) Response to abnormal liver blood tests. They are not designed to deal with the management of the underlying liver disease.

Original languageEnglish
Pages (from-to)6-19
Number of pages14
JournalGut
Volume67
Issue number1
Early online date9 Nov 2017
DOIs
Publication statusPublished - Jan 2018

Keywords

  • alcoholic liver disease
  • fibrosis
  • liver
  • nonalcoholic steatohepatitis
  • Humans
  • Risk Factors
  • Non-alcoholic Fatty Liver Disease/diagnosis
  • Liver Function Tests/methods
  • Chemical and Drug Induced Liver Injury/diagnosis
  • Liver Diseases/diagnosis
  • Algorithms
  • Biomarkers/blood
  • Disease Management
  • Evidence-Based Medicine/methods

Fingerprint Dive into the research topics of 'Guidelines on the management of abnormal liver blood tests'. Together they form a unique fingerprint.

  • Cite this

    Newsome, P. N. G., Cramb, R., Davison, S. M., Dillon, J. F., Foulerton, M., Godfrey, E. M., Hall, R., Harrower, U., Hudson, M., Langford, A., Mackie, A., Mitchell-Thain, R., Sennett, K., Sheron, N. C., Verne, J., Walmsley, M., & Yeoman, A. (2018). Guidelines on the management of abnormal liver blood tests. Gut, 67(1), 6-19. https://doi.org/10.1136/gutjnl-2017-314924